本报讯(记者袁传玺) 日前，礼来制药旗下穆峰达(替尔泊肽注射液多剂量预装笔)在京东健康股份有限公司(以下简称"京东健 康")线上首发。穆峰达作为全球首个且目前唯一获批用于2型糖尿病和长期体重管理的GIP/GLP-1受体激 动剂，自上市以来便以其独特的双重作用机制和显著的疗效，赢得了广大患者的信赖与好评。此次替尔 泊肽注射液多剂量预装笔，是礼来制药推出的新型注射装置，将为患者带来全新的选择。 京东健康相关负责人表示："我们非常高兴能够与礼来制药合作，率先引入穆峰达多剂量预装笔。这款 改进剂型将在京东买药秒送独家首发，并同步在京东买药上线，给患者带来更加方便、快捷的购买体 验。未来，我们将继续与全球药企紧密合作，共同推动新特药的普及和可及性，为更多患者提供精准、 高效的治疗方案。" 随着穆峰达多剂量预装笔在京东健康平台的线上首发，相信将有更多2型糖尿病和肥胖患者从中受益， 实现更加健康、美好的生活。 此次，礼来制药改进了穆峰达的注射装置。穆峰达(替尔泊肽注射液多剂量预装笔)采用了创新的"4剂集 成"设计，每支笔包含四个固定剂量，每周使用一个剂量，即可满足患者一个月的治疗需求。这一设计 不仅简化了用药流程，减少了患 ...

Group 1 - The core viewpoint of the article highlights the launch of Eli Lilly's Mounjaro® (tirzepatide injection multi-dose prefilled pen) on JD Health, marking it as the first and only GIP/GLP-1 receptor agonist approved for type 2 diabetes and long-term weight management [1][2] - Mounjaro® features an innovative "4-dose integration" design, allowing patients to use one fixed dose per week, thus simplifying the medication process and improving adherence [1] - The multi-dose prefilled pen can be stored at room temperature not exceeding 30°C for 30 days after the first use, enhancing convenience for patients during travel or daily use [1] Group 2 - The user experience of Mounjaro® multi-dose prefilled pen is emphasized, with simple operation steps and a fine needle that reduces pain during injection, improving patient comfort [2] - JD Health expresses excitement about collaborating with Eli Lilly to exclusively launch Mounjaro® on their platform, aiming to enhance accessibility and convenience for patients [2] - The launch of Mounjaro® is expected to benefit more patients with type 2 diabetes and obesity, promoting healthier lifestyles [2]

近日，中共中央办公厅、国务院办公厅正式出台《育儿补贴制度实施方案》，明确对3岁以下婴幼儿发 放育儿补贴，能够有效降低家庭生育成本，更利好母婴刚需消费市场升级。 然而在机会的另一面，母婴品牌也面临着流量成本攀升、用户注意力分散、产品同质化等问题。更深层 的变化在于，年轻父母在育儿方面正变得格外"挑剔"。京东健康营养保健业务部母婴营养业务负责人指 出："母婴用户整体的购买需求从之前的'基础预防'，慢慢转变成了现在的'科学育儿'。" 延续这一思路，为了方便缺铁孕妈妈对抗血糖升高问题，PERDAYS研发"无糖活性铁剂"，高效补铁的 同时不破坏血糖管理节奏。 这一转变正推动市场显著增长。第三方数据显示，2025年，国内母婴营养品市场规模预计将达1300亿 元；在精细化育儿趋势下，新一代父母对科学配比、全周期营养管理的需求激增，也推动了DHA、益 生菌等细分品类快速增长。 面对需求升级和市场变化，母婴营养品牌也在同步进化其营销策略。作为京东健康"健步为赢"优秀商家 标杆，澳洲品牌PERDAYS，就走出了一条"科学孕养"的差异化路径。 PERDAYS来自澳洲，定位为"新时代女性的全周期科学孕养品牌"。跳出孕期DHA、钙铁锌 ...

Core Points - JD Health (06618.HK) announced that it will hold a board meeting on August 14, 2025, to approve the unaudited interim results for the six months ending June 30, 2025, and to consider the proposal for an interim dividend, if any [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何 責任。 JD Health International Inc. 京東健康股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6618（港幣櫃台）及86618（人民幣櫃台）） 董事會會議日期 京东健康股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本公司將於 2025年8月14日（星期四）舉行董事會會議，以（其中包括）批准本公司及其子公司截至2025 年6月30日止六個月之未經審計中期業績及其發佈，以及考慮建議派付中期股息（如有）。 本公司管理層將於2025年8月14日（星期四）下午七時正（北京╱香港時間）舉行電話會議， 以討論本公司及其子公司截至2025年6月30日止六個月的中期業績。 有意參加電話會議的參與者請在電話會議計劃開始時間前至少10分鐘進行撥入，並按照 提示輸入參會者密碼以進入電話會議。 撥入號碼： 普通話頻道參會者密碼：452174 英文頻道參會者密碼： 182612 ...

消息上，近期互联网医疗行业迎来多重利好消息，涉及政策支持、技术创新、市场表现及企业合作等多 个方面。 2025年7月，国家药监局发布《优化全生命周期监管支持高端医疗器械创新发展有关举措》，重点支持 AI影像诊断、手术机器人、脑机接口等创新医疗器械发展，并加快制定相关技术标准。北京市"AI+医 药健康"行动计划：提出到2027年构建"人工智能+医药健康"创新生态体系，推动30个以上核心技术和创 新产品落地转化。 港股互联网医疗股拉升走高，其中，平安好医生涨近9%领涨且刷新阶段新高 ，阿里健康涨超4%，京东 健康涨3.4%。 有分析指出，总体来看，互联网医疗行业在政策、技术、资本和市场需求的共同推动下，正迎来快速发 展期，未来在AI诊疗、远程医疗、数字疗法等领域仍有较大增长空间。(格隆汇） | 代码 | 名称 | 最新价 | 涨跌幅 √ | | --- | --- | --- | --- | | 01833 | 平安好医生 | 11.740 | 8.70% | | 00241 | 阿里健康 | 5.060 | 4.33% | | 06618 | 京东健康 | 51.650 | 3.40% | | 06086 | ...

Core Insights - The article highlights the launch of a new oral Bcl-2 selective inhibitor, Lisangtuo® (generic name: Lishatoklaku), developed by Ascentage Pharma, which is now exclusively available on JD Health [1][3] - Lisangtuo® is the first domestically approved original Bcl-2 inhibitor in China and the second globally, aimed at treating adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have undergone at least one prior systemic therapy including BTK inhibitors [1][3] - The drug works by selectively inhibiting the Bcl-2 protein, restoring normal apoptosis in tumor cells, and is expected to have fewer interactions with common drugs and more controllable effects on platelets compared to traditional CLL/SLL medications [1][3] Industry Context - The development of Bcl-2 inhibitors is challenging due to complex protein-protein interactions and the need for the drug to penetrate both the cell membrane and mitochondrial membranes [3] - Prior to Lisangtuo®, no Bcl-2 inhibitors had been approved for CLL/SLL treatment in China, indicating a significant advancement in the field [3] - The successful launch of Lisangtuo® represents a major step for China in the treatment of hematological malignancies and showcases Ascentage Pharma's leading capabilities in global innovative research and development [3] Distribution Strategy - JD Health is leveraging its capabilities in pharmaceutical supply chain and healthcare services to provide comprehensive support, including drug consultation, doctor consultations, and efficient delivery for users in need [4]

Core Insights - The article highlights the resurgence of medical AI at the WAIC, with major tech companies and startups re-engaging in the sector, indicating a shift in focus towards healthcare applications [1][2] Group 1: Medical AI Landscape - Major tech companies like Tencent, Alibaba, and ByteDance are refocusing on medical AI as a core business area, showcasing advanced AI solutions at WAIC [1] - Key topics discussed include AI drug development, clinical applications, and the democratization of healthcare, with participation from pharmaceutical and medical device companies [1] Group 2: Pathways of Medical AI Development - Pathway One: Fragmented AI is beginning to systematically empower healthcare, moving from isolated applications to integrated solutions that address broader healthcare needs [2][3] - The emergence of intelligent agents allows for proactive, goal-driven interactions in healthcare, enhancing the efficiency of medical processes [3][4] Group 3: Intelligent Agents and User Engagement - Intelligent agents like Tencent's "Health Management Assistant" integrate various health tools, enabling continuous user engagement and proactive health management [3][4] - Startups are also leveraging AI to enhance low-digitalization scenarios, such as simulating patient interactions for training purposes [5] Group 4: Clinical Applications and Specialized Models - Pathway Two: The focus is shifting from general applications to specialized clinical models, with companies like JD Health leading the way in developing tailored AI solutions for specific medical fields [6][7] - JD Health's "京医千询2.0" aims to enhance AI capabilities in clinical settings, focusing on evidence-based data and interactive simulations [6][7] Group 5: AI in Medical Imaging - Union Medical is noted for its advancements in medical imaging AI, showcasing a unique intelligent agent capable of detecting multiple chest abnormalities with high accuracy [8][9] - The intelligent agent demonstrates significant efficiency improvements in diagnostic processes, highlighting the potential of AI in enhancing clinical workflows [9] Group 6: Standardization and Regulation - The need for a comprehensive regulatory framework for medical AI is emphasized, with initiatives like the "AI Doctor" standard being introduced to ensure quality and safety in AI applications [11][12] - The establishment of standards is seen as a crucial step towards systematic and regulated development in the medical AI sector [12] Group 7: Future Outlook for Medical AI - Despite challenges in monetization and ethical considerations, there is optimism about the potential for medical AI to become an integral part of the healthcare ecosystem [13][14] - Collaborative efforts among government, healthcare institutions, and tech companies are paving the way for a more robust medical AI landscape, with the possibility of achieving viable business models in the near future [14]

Summary of Key Points Core Viewpoint - The report highlights the top short-selling stocks in the market, indicating significant short-selling activity and potential investor sentiment towards these companies. Group 1: Top Short-Selling Ratios - JD Health (86618) has the highest short-selling ratio at 100.00% [1][2] - Hang Seng Bank (80011) follows with a short-selling ratio of 88.44% [1][2] - SenseTime (80020) has a short-selling ratio of 76.25% [1][2] Group 2: Top Short-Selling Amounts - Xiaomi Group (01810) leads in short-selling amount with 2.209 billion [1][2] - Tencent Holdings (00700) has a short-selling amount of 0.955 billion [1][2] - WuXi AppTec (02359) reports a short-selling amount of 0.698 billion [1][2] Group 3: Top Short-Selling Deviations - Hang Seng Bank (80011) has the highest deviation value at 48.82% [1][2] - JD Health (86618) follows with a deviation value of 45.78% [1][2] - Uni-President China (00220) has a deviation value of 33.70% [1][2]

Core Viewpoint - The article highlights the significant role of JD Health in promoting liver health awareness and improving liver disease prevention and treatment through its digital healthcare services and pharmaceutical supply chain advantages [2][3][4]. Group 1: Industry Context - The number of liver disease patients in China is substantial, including carriers of viral hepatitis (HBV/HCV), long-term alcohol consumers, individuals with metabolic syndrome, and drug abusers [2]. - The liver performs over 500 essential physiological functions daily, and its health directly impacts overall quality of life [2]. Group 2: Company Initiatives - JD Health hosted the "Scientific Liver Protection, Healthy Future" industry forum to showcase its efforts in liver disease management and support for pharmaceutical companies [2]. - JD Health has established a comprehensive digital service system covering the entire liver disease management cycle, leveraging its pharmaceutical supply chain and digital capabilities [3]. - The company reported a more than 40% year-on-year increase in sales of antiviral and liver-protecting traditional Chinese medicine in the past year, particularly in lower-tier markets [3]. Group 3: Consumer Trends - A report released by JD Health and Zhongkang Technology indicates a growing trend in liver health product consumption, with a projected 26% year-on-year growth in 2024 [4]. - Patients are spending an average of over 1,800 yuan annually on liver health products, with a high repurchase rate exceeding 50% and an average of nearly 7 purchases per year [4]. Group 4: Future Directions - JD Health is forming a "Scientific Liver Protection" alliance with various pharmaceutical companies to enhance public awareness of liver diseases and promote standardized health education [5]. - The company aims to build a more comprehensive disease prevention and patient service system, focusing on early screening and treatment of liver diseases [5].